Today Almac Diagnostics announced a major study analysing colorectal polyp tissue samples using its novel Colorectal Cancer DSA? microarray. The DSA? research tool focuses on the transcriptome of an individual disease, in this case colorectal cancer, and contains significant additional data, relevant to the disease of interest that is not available on other generic microarrays.
Binghamton University Professor Gary D. James is hoping his new book will take the stress out of researching stress. Offering guidance on topics ranging from the best ways to collect saliva and urine to working with special populations including pregnant women and the elderly, James expects that the book will help students and professionals design more effective field studies and models for stress measurement.
First large, randomized Phase III study of ERBITUX with chemotherapy in recurrent and/or metastatic head and neck cancer meets primary endpoint of improving overall survival.
Kinetic Concepts, Inc. (NYSE:KCI), a global medical technology company with leadership positions in advanced wound care and therapeutic surfaces, issued a statement on the recently-released final competitive bidding rule by the Centers for Medicare and Medicaid Services (“CMS”).
The Human Fertilisation and Embryology Authority (HFEA) is launching a public consultation on April 4 to find the best way to reduce avoidable problems for IVF children and their mothers who can suffer serious and long-term complications from twin births.
Cephalon, Inc. (Nasdaq: CEPH) announced that it has received an approvable letter, together with draft labeling, from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for NUVIGIL(TM) (armodafinil) Tablets [C-IV] for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift work sleep disorder (SWSD).
Theravance, Inc. (NASDAQ: THRX) announced the results of two studies in an ongoing Phase 2b clinical program to assess the efficacy and safety of the investigational bronchodilators GSK642444 (‘444) and GSK159797 (‘797), the lead long-acting Beta2 agonist (LABA) compounds in the Beyond Advair collaboration with GlaxoSmithKline (GSK).
Cell Genesys, Inc. (Nasdaq: CEGE) announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer (HRPC).
Boston Scientific Corporation announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan.
Research into cancer, anticancer treatments, and ageing has been advanced through the identification of the composition of human telomerase – an enzyme integral to 85% of all cancers.